Gilteritinib (Xospata)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 20:48, 5 May 2023 by Jwarner (talk | contribs)
Jump to navigation Jump to search

Mechanism of action

Tyrosine kinase inhibitor of FLT3, AXL, and ALK

Diseases for which it is used

History of changes in FDA indication

  • 2018-11-28: Initial FDA approval for treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. (Based on ADMIRAL)

History of changes in EMA indication

  • 2019-10-24: Initial authorization

Patient Drug Information

Also known as

  • Code name: ASP2215
  • Brand name: Xospata

References

  1. ↑ Gilteritinib (Xospata) Package Insert
Retrieved from "https://hemonc.org/w/index.php?title=Gilteritinib_(Xospata)&oldid=70204"